hotspot -WSS

hotspot

author：hotspot 2025-10-01 17:56:41 - browse：65394

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Second xenotransplant done with gene

hotspot

WSS

Medical student insurance fails on mental health care coverage

Australia’s approach to dialysis celebrates life

How a symptom of dementia informs our understanding of creativity

Ukraine and a new approach to mental health in war

Emergency workers more likely to restrain Black patients: study

CommonSpirit Health keeps growing, even as it loses money

explore

hotspot

leisure time

Alkermes shareholders re

Radiation, mainstay of cancer treatment, begins a fade

Jerome Adams on the need for new antivirals for Covid

Ukraine and a new approach to mental health in war

Apple is now the first public company to be valued at $3 trillion

What do new weight loss drugs mean for bariatric surgery?

Medical leaders decry Supreme Court decision on affirmative action

EpiPen alternative approval delay highlights citizen petition issue

Trump demands the U.S. pay no more for drugs than other countries … again

It's been 20 years since Dolly the sheep. Where's my clone?

focus

2024 GOP presidential candidates spar over abortion in debate

CDC advisers recommend seasonal use of Pfizer RSV shot

AstraZeneca bets AAV gene therapy will still deliver the goods

In science, is the line between industry and academia shifting?

CommonSpirit Health keeps growing, even as it loses money

EpiPen alternative approval delay highlights citizen petition issue

knowledge

explore

hotspot

focus